foxo4 dri senescence FOXO4-DRI — ≥99% Purity, COA Included FOXO4-DRI | Baltic BioLabs
FOXO4 DRI Baltic BioLabs FOXO4 DRI: Human Trial Status, Cancer Research & Senolytic Data The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications FOXO4 DRI: A Breakthrough Peptide Targeting Aging at Its Roots PARTICLE, s. r. o.
Pay in 4 interest-free payments of $7.41 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12



